TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10777467
Drug: Paclitaxel and
Normalized name: paclitaxel and encequidar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel and carboplatin in combination with thoracic radiation therapy
Study: 10777467
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality therapy with thoracic radiation therapy
Study: 25127924
Drug: Probiotic (Bacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic (Bacillus coagulans GBI-30, 6086 capsule)
Study: 16421034
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment (lanzoprazole, clarithromycin, and amoxicillin) for 8 days
Study: 16421034
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii plus inulin (SbI) daily for 8 weeks
Study: 16421034
Drug: Lactobacillus acidophilus
Normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus acidophilus LB (LB) daily for 8 weeks
Study: 14519710
Drug: CT-3 (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-3 (four 10-mg capsules per day for the first 4 days, then 8 capsules per day in 2 daily doses for the following 3 days)
Study: 10792337
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine oestrogen (CEE)
Study: 10792337
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg conjugated equine oestrogen (CEE)
Study: 10792337
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg and 0.3 mg conjugated equine oestrogen (CEE)
Study: 8785958
Drug: Diphtheria-tetanus vaccine
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria-tetanus vaccine adsorbed to aluminium hydroxide
Study: 8785958
Drug: Diphtheria-tetanus vaccine
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria-tetanus vaccine adsorbed to calcium phosphate
Study: 26967157
Drug: Participants who
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants who were housewives, knew three or more correct symptoms of dengue, knew at least one correct treatment for dengue, knew someone who had dengue, had children sleeping under a mosquito net, or perceived a change in mosquito amounts.
Study: 18988089
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin cream 0.025%
Study: 16859791
Drug: Usual dopaminergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual dopaminergic treatment in PD patients
Study: 16859791
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of dopaminergic medication in PD patients
Study: 9361930
Drug: CsA monitoring
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA monitoring with T6 (levels obtained 6 h after the morning dose)
Study: 9496526
Drug: Cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 200 mg intravenously
Study: 26897613
Drug: Unmet information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unmet information needs related to cancer/treatment
Study: 23177487
Drug: Original clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original clopidogrel bisulphate (600 mg loading dose)
Study: 23177487
Drug: Clopidogrel hydrochloride
Normalized name: Clopidogrel hydrochloride
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel hydrochloride (600 mg loading dose)
Study: 23177487
Drug: Clopidogrel besylate
Normalized name: Clopidogrel besylate
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel besylate (600 mg loading dose)
Study: 23177487
Drug: Prasugrel (given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (given for 10 days after clopidogrel treatments)
Study: 19523613
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of IM P-in-oil daily for 11 days (group 2)
Study: 19523613
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of IM P-in-oil daily for 6 weeks (group 1)
Study: 16855070
Drug: Febuxostat 80
Normalized name: febuxostat 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat 80 mg once daily, Indomethacin 50 mg twice daily
Study: 16855070
Drug: Febuxostat 80
Normalized name: febuxostat 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat 80 mg, Naproxen 500 mg twice daily
Study: 6359877
Drug: Warfarin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin and dipyridamole treatment
Study: 29747292
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of renal replacement therapy (RRT) in the ELAIN trial (KDIGO stage 2 of AKI)
Study: 29747292
Drug: Late initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Late initiation of renal replacement therapy (RRT) in the ELAIN trial
Study: 26449391
Drug: Single-dose i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose i.v. fosaprepitant 150 mg
Study: 22951160
Drug: Perioperative mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative mitomycin C (MMC) instillation (40 mg MMC in 40 mL saline administered within 6 hours of surgery) followed by delayed BCG instillations (once a week for 6 weeks, 5 x 10^8 colony-forming units in 50 mL saline)
Study: 20860912
Drug: Vildagliptin 10
Normalized name: vildagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 10 mg twice daily
Study: 20860912
Drug: Vildagliptin 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 25 mg twice daily
Study: 12882841
Drug: Insulin (premixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (premixed 30% soluble and 70% NPH insulin, two daily injections)
Study: 12882841
Drug: Glibenclamide (3.5-10.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (3.5-10.5 mg daily)
Study: 12882841
Drug: Insulin (premixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (premixed 30% soluble and 70% NPH insulin, two daily injections) and Glibenclamide (3.5-10.5 mg daily)
Study: 8641491
Drug: Low dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage of FSH (75 units daily)
Study: 8641491
Drug: High dosage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dosage of FSH (150 units daily)
Study: 31310319
Drug: Genetically higher
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically higher serum parathyroid hormone (S-PTH) concentrations
Study: 9255751
Drug: Transdermal 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17 beta‐estradiol (0.05 mg/day once a week)
Study: 9255751
Drug: Oral norethisterone
Normalized name: ethisterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral norethisterone acetate (NETA) 1 mg
Study: 2893446
Drug: Naloxone 1
Normalized name: naloxone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 1 mg
Study: 2781424
Drug: Naloxone 4
Normalized name: naloxone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 4 mg
Study: 2893446
Drug: Timolol 2
Normalized name: timolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 2 mg
Study: 18361004
Drug: ECMO as
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECMO as rescue therapy
Study: 16875188
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (immobilization, physiotherapy, drug therapy, steroid injections)
Study: 12491501
Drug: L-PAM (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-PAM (in premenopausal women)
Study: 12491501
Drug: L-PAM (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-PAM (in patients with > or = 4 positive lymph nodes)
Study: 1497689
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg ISMN in the morning
Study: 1497689
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ISMN b.i.d. morning and early afternoon
Study: 6128331
Drug: Piracetam (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (40 g, i.v.)
Study: 28408193
Drug: Imipramine (25-75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (25-75 mg daily for 10 weeks)
Study: 11759980
Drug: 50 mcg
Normalized name: D3, 50 mcg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mcg oral misoprostol every 4 hours
Study: 11759980
Drug: 50 mcg
Normalized name: D3, 50 mcg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mcg oral misoprostol every 6 hours
Study: 9158880
Drug: Single-dose (SD)
Normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose (SD) MDL 26479 ranging from 2 to 465 mg
Study: 9158880
Drug: Multiple-dose (MD)
Normalized name: miconazole nitrate Topical Solution [Nail MD]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose (MD) MDL 26479 at doses of 30, 60, and 120 mg administered twice daily for 28 days
Study: 9158880
Drug: Single-dose (SD)
Normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose (SD) and multiple-dose (MD) MDL 26479
Study: 7962378
Drug: Pulsatile subcutaneous
Normalized name: PULSATILLA PRATENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile subcutaneous gonadotrophin administration
Study: 7962378
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily bolus intramuscular gonadotrophin administration
Study: 3656939
Drug: Low concentration
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low concentration dialysate (L; Na 126 mmol/liter)
Study: 11552204
Drug: Carbidopa L-dopa
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbidopa L-dopa (Sinemet)
Study: 26443493
Drug: Stepped care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped care trauma-focused cognitive behavioral therapy (SC-TF-CBT)
Study: 26443493
Drug: Standard trauma-focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard trauma-focused cognitive behavioral therapy (TF-CBT)
Study: 21400797
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion of analgesics and anaesthetics
Study: 10426243
Drug: Paracervical block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracervical block using 10 mL of 2% lignocaine
Study: 7564725
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral lysine acetylsalicylate (900 mg) and metoclopramide (10 mg)
Study: 11200792
Drug: Oral sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sumatriptan (100 mg)
Study: 7564725
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral lysine acetylsalicylate and metoclopramide
Study: 30768732
Drug: Eplerenone 50
Normalized name: eplerenone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 50 mg/day (eGFR ≥ 50 mL/min/1.73 m2)
Study: 30768732
Drug: Eplerenone 25
Normalized name: eplerenone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 25 mg/day (eGFR 30-49 mL/min/1.73 m2)
Study: 30768732
Drug: Placebo (eGFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (eGFR ≥ 50 mL/min/1.73 m2)
Study: 30768732
Drug: Placebo (eGFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (eGFR 30-49 mL/min/1.73 m2)
Study: 30768732
Drug: Eplerenone (eGFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (eGFR 30-49 mL/min/1.73 m2)
Study: 15465627
Drug: Polymorphisms of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymorphisms of genes located on chromosome 10 involved in cholesterol metabolism (LIPA, CH25H, FLJ22476)
Study: 11460544
Drug: Glycolic acid
Normalized name: Glycolic Acid
DrugBank: Glycolic acid (DB03085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycolic acid cream (8% concentration)
Study: 11460544
Drug: Glycolic acid
Normalized name: Glycolic Acid
DrugBank: Glycolic acid (DB03085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycolic acid cream (4% concentration)
Study: 11460544
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream (vehicle)
Study: 9879196
Drug: Hypotensive anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotensive anesthesia with prostaglandin E1 (PGE1) and autologous blood transfusion (400 ml)
Study: 19793402
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg scopolamine
Study: 26665759
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy combined with Prolit super septo (10 day course)
Study: 12609560
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg per day plus CR BNO 1055 (20 mg of herbal drug) for 12 months (intervention group, n=90)
Study: 12609560
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg per day (usual-care group, n=46)
Study: 9466128
Drug: 9 g
Normalized name: Publix Pen Needle 29 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 g of fish oil per day
Study: 9466128
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g of fish oil (placebo)
Study: 9466128
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of fish oil per day
Study: 9466128
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g of fish oil per day
Study: 8448746
Drug: UFT (300-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (300-400 mg/d for 2 years)
Study: 31109001
Drug: Sevelamer carbonate
Normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer carbonate (4.8 g) three times a day for 12 weeks
Study: 27755181
Drug: I‐gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: I‐gel
Study: 26486857
Drug: Customized Short
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Customized Short Messaging Service (SMS) reminders for 2 months, including personalized daily medication reminders and twice weekly health information SMS.
Study: 21177789
Drug: NNC126‐0083 (0.01,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC126‐0083 (0.01, 0.02, 0.04, and 0.08 mg/kg) given subcutaneously once weekly for 3 weeks
Study: 21177789
Drug: NNC126‐0083 (0.01,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC126‐0083 (0.01, 0.02, 0.04, and 0.08 mg/kg)
Study: 19856792
Drug: Rabeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (20 mg) - Itopride (150 mg) fixed dose combination (FDC)
Study: 12571611
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg b.i.d.
Study: 1710669
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment program for pain control
Study: 6367859
Drug: Five drugs
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five drugs (CMFVP)
Study: 6367859
Drug: Three drugs
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three drugs (CMF)
Study: 6367859
Drug: Non-cross-reacting drug
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-cross-reacting drug combination
Study: 29411270
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E softgel (300 mg/day)
Study: 23242728
Drug: Polyhexamethylene biguanide
Normalized name: Polyhexamethylene Biguanide
DrugBank: Polihexanide (DB12277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyhexamethylene biguanide vaginal suppositories
Study: 23242728
Drug: Chlorhexidine digluconate
Normalized name: Chlorhexidine digluconate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine digluconate vaginal suppositories
Study: 20728066
Drug: 1mg morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg morphine plus 5mg ketamine/bolus (group MK)
Study: 20728066
Drug: 2mg/bolus morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2mg/bolus morphine (group MO)
Study: 18093117
Drug: Medical on-treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medical on-treatment review
Study: 14580054
Drug: Dolasetron 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron 1.8 mg kg(‐1)
Study: 14580054
Drug: Ondansetron 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.15 mg kg(‐1)
Study: 31149930
Drug: Pregabalin alone
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin alone (150 mg preoperatively and twice daily for 14 days)
Study: 29566463
Drug: Twice-weekly supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly supervised physical training sessions in a fitness center
Study: 23154549
Drug: Endostatin treatment
Normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endostatin treatment (paclitaxel + carboplatin + endostatin)
Study: 17404163
Drug: Sibutramine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine (15 mg)
Study: 19937362
Drug: Sibutramine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine plus Metformin (15 mg + 1,700 mg)
Study: 19114406
Drug: Test meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test meal (200 g boiled white rice with 50 g natto, 60 g Japanese yams, and 40 g okras)
Study: 19114406
Drug: Control meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control meal (200 g white rice with non-viscous boiled soybeans, potatoes, and broccoli)
Study: 12530340
Drug: Risperidone (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (daily dosing)
Study: 12530340
Drug: Risperidone (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (twice daily dosing)
Study: 1860008
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg/24 h, increased to 100 mg/24 h after 16 months, thiazide added after 30 months)
Study: 6225482
Drug: spectinomycin 2
Normalized name: spectinomycin 2 g intramuscular powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: spectinomycin 2 g intramuscularly (group A)
Study: 6225482
Drug: cefamandole 1
Normalized name: cefamandole 1 g injectable powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: cefamandole 1 g intramuscularly after probenecid 1 g orally (group B)
Study: 6225482
Drug: cefaclor 3
Normalized name: cefaclor 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cefaclor 3 g orally with probenecid 1 g orally (group C)
Study: 6225482
Drug: cefaclor 3
Normalized name: cefaclor 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cefaclor 3 g orally (group D)
Study: 25828362
Drug: secukinumab 1
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: secukinumab 1 × 3 mg/kg on Day 1
Study: 25828362
Drug: secukinumab 1
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: secukinumab 1 × 10 mg/kg on Day 1
Study: 25828362
Drug: secukinumab 3
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: secukinumab 3 × 10 mg/kg on Days 1, 15 and 29
Study: 3440093
Drug: Meptazinol (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol (0.7 mg kg‐1 and 1.4 mg kg‐1)
Study: 3440093
Drug: Pentazocine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine (0.3 mg kg‐1 and 0.6 mg kg‐1)
Study: 25178454
Drug: Rectal temperature
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal temperature (Trec)
Study: 17408662
Drug: SCH 503034
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 503034 200 mg plus PEG‐IFN‐alpha‐2b
Study: 17408662
Drug: SCH 503034
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 503034 400 mg plus PEG‐IFN‐alpha‐2b
Study: 17408662
Drug: SCH 503034
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 503034 200 mg alone
Study: 17408662
Drug: SCH 503034
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 503034 400 mg alone
Study: 15570081
Drug: Low-dose MPH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose MPH (0.3 mg/kg; maximum dose, 10 mg bid)
Study: 15570081
Drug: Moderate-dose MPH
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate-dose MPH (0.6 mg/kg; maximum dose, 20 mg bid)
Study: 11257278
Drug: Lower plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower plasma bilirubin levels in males (12.5 micromol/l)
Study: 8852539
Drug: Lacidipine (4-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine (4-6 mg once daily)
Study: 8852539
Drug: Hydrochlorothiazide (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (12.5 mg, titrated to 25 mg if required)
Study: 2242077
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg temazepam
Study: 1967533
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg temazepam
Study: 2242077
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of temazepam
Study: 2242077
Drug: Temazepam (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam (all doses)
Study: 31965772
Drug: Famciclovir 250
Normalized name: famciclovir 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir 250 mg thrice daily for 1 week
Study: 28056794
Drug: Mercury concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mercury concentration in toenails (μg per gram)